SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Miller Eric Alejandro (Last) (First) (Middle) C/O ACADIA PHARMACEUTICALS INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 (Street) SAN DIEGO CA 92130 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/02/2018	3. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ ACAD ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Controller & PAO	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,212	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	05/29/2024	Common Stock	7,500	20.65	D
Employee Stock Option (Right to Buy)	(2)	01/25/2025	Common Stock	3,900	32.28	D
Employee Stock Option (Right to Buy)	(3)	01/05/2026	Common Stock	6,615	29.24	D
Employee Stock Option (Right to Buy)	(4)	03/07/2027	Common Stock	7,350	36.54	D
Employee Stock Option (Right to Buy)	(5)	09/06/2027	Common Stock	9,187	35.8	D
Employee Stock Option (Right to Buy)	(6)	04/06/2028	Common Stock	5,570	16.5	D
Employee Stock Option (Right to Buy)	(7)	10/14/2028	Common Stock	3,342	21.28	D
Restricted Stock Units	(8)	(8)	Common Stock	1,671	(9)	D

Explanation of Responses:

1. This option is fully vested and exercisable.

2. 25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2016, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

3. 25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2017, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

4. 25% of the shares subject to the Stock Option vested and became exercisable on March 8, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

5. 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

6. 25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

7. 25% of the shares subject to the Stock Option vest and become exercisable on October 15, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

8. The restricted stock units vest in four equal annual installments beginning October 15, 2019.

9. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

	/s/ Eric Alejandro Miller	11/09/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY


	Know all by these presents, that the undersigned hereby authorizes Austin D.
Kim, Reena Desai or Martin Choy to execute for and on behalf of the undersigned,
in the undersigned's capacity as an officer of ACADIA Pharmaceuticals Inc. (the
"Company"), Forms 3, 4 and 5 and any Amendments thereto, and cause such form(s)
to be filed with the Securities and Exchange Commission pursuant to Section
16(a) of the Securities Exchange Act of 1934, relating to the undersigned's
beneficial ownership of securities in the Company.  The undersigned hereby
grants to such attorney-in-fact full power and authority to do and perform any
and every act and thing whatsoever requisite, necessary, or proper to be done in
the exercise of any of the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might or could do if personally present,
with full power of substitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or substitute or substitutes of such
attorney-in-fact, shall lawfully do or cause to be done by virtue of this power
of attorney and the rights and powers herein granted.  The undersigned
acknowledges that the foregoing attorney-in-fact, in serving in such capacity at
the request of the undersigned, is not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of, and transactions in, securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorney-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 9th day of November 2018.



							/s/ Eric Miller